000 01910 a2200469 4500
005 20250515110812.0
264 0 _c20080603
008 200806s 0 0 eng d
022 _a1078-0432
024 7 _a10.1158/1078-0432.CCR-07-4097
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFox, Elizabeth
245 0 0 _aA phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
_h[electronic resource]
260 _bClinical cancer research : an official journal of the American Association for Cancer Research
_cFeb 2008
300 _a1111-5 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
650 0 4 _aAdolescent
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aChild
650 0 4 _aChild, Preschool
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aHumans
650 0 4 _aMaximum Tolerated Dose
650 0 4 _aNeoplasm Recurrence, Local
_xdrug therapy
650 0 4 _aNeoplasms
_xdrug therapy
650 0 4 _aSulfonamides
_xadministration & dosage
650 0 4 _aTubulin Modulators
_xadministration & dosage
700 1 _aMaris, John M
700 1 _aWidemann, Brigitte C
700 1 _aGoodspeed, Wendy
700 1 _aGoodwin, Anne
700 1 _aKromplewski, Marie
700 1 _aFouts, Molly E
700 1 _aMedina, Diane
700 1 _aCohn, Susan L
700 1 _aKrivoshik, Andrew
700 1 _aHagey, Anne E
700 1 _aAdamson, Peter C
700 1 _aBalis, Frank M
773 0 _tClinical cancer research : an official journal of the American Association for Cancer Research
_gvol. 14
_gno. 4
_gp. 1111-5
856 4 0 _uhttps://doi.org/10.1158/1078-0432.CCR-07-4097
_zAvailable from publisher's website
999 _c17786022
_d17786022